These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38219628)
1. Bionanoengineered 2D monoelemental selenene for piezothrombolysis. Hu H; Xia L; Wang J; Huang X; Zhao Q; Song X; Hu L; Ren S; Lu C; Ren Y; Qian X; Feng W; Wang Z; Chen Y Biomaterials; 2024 Mar; 305():122468. PubMed ID: 38219628 [TBL] [Abstract][Full Text] [Related]
2. Platelet Membrane Cloaked Nanotubes to Accelerate Thrombolysis by Thrombus Clot-Targeting and Penetration. Liu B; Victorelli F; Yuan Y; Shen Y; Hong H; Hou G; Liang S; Li Z; Li X; Yin X; Ren F; Li Y Small; 2023 Jan; 19(4):e2205260. PubMed ID: 36424174 [TBL] [Abstract][Full Text] [Related]
3. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Collen D; Stassen JM; Verstraete M J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615 [TBL] [Abstract][Full Text] [Related]
4. Bacteria-propelled microtubular motors for efficient penetration and targeting delivery of thrombolytic agents. Xie S; Mo C; Cao W; Xie S; Li S; Zhang Z; Li X Acta Biomater; 2022 Apr; 142():49-59. PubMed ID: 35158079 [TBL] [Abstract][Full Text] [Related]
5. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052 [TBL] [Abstract][Full Text] [Related]
7. A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs. Hu L; Xu J; Zhang W; Wang J; Fang N; Luo Y; Xu L; Liu J; Zhang Y; Ran H; Guo D; Zhou J Int J Nanomedicine; 2022; 17():5229-5246. PubMed ID: 36388875 [TBL] [Abstract][Full Text] [Related]
8. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779 [TBL] [Abstract][Full Text] [Related]
9. Intrinsic Biotaxi Solution Based on Blood Cell Membrane Cloaking Enables Fullerenol Thrombolysis Chen K; Wang Y; Liang H; Xia S; Liang W; Kong J; Liang Y; Chen X; Mao M; Chen Z; Bai X; Zhang J; Li J; Chang YN; Li J; Xing G ACS Appl Mater Interfaces; 2020 Apr; 12(13):14958-14970. PubMed ID: 32142246 [TBL] [Abstract][Full Text] [Related]
10. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759 [TBL] [Abstract][Full Text] [Related]
11. Bacteria-Templated and Dual Enzyme-Powered Microcapsule Motors To Promote Thrombus Penetration and Thrombolytic Efficacy. Xie S; Li S; Cao W; Mo C; Zhang Z; Huang K; Li X ACS Appl Mater Interfaces; 2022 Aug; 14(33):37553-37565. PubMed ID: 35948498 [TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
13. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model. Matsuo O; Bando H; Okada K; Tanaka K; Tsukada M; Iga Y; Arimura H Thromb Res; 1986 Apr; 42(2):187-94. PubMed ID: 3087008 [TBL] [Abstract][Full Text] [Related]
14. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy. Chen HA; Ma YH; Hsu TY; Chen JP Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917 [TBL] [Abstract][Full Text] [Related]
15. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
17. New developments in thrombolytic therapy. Collen DC; Gold HK Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114 [TBL] [Abstract][Full Text] [Related]
18. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase. Gurewich V Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871 [No Abstract] [Full Text] [Related]